This presentation offers a comprehensive examination of Biliary Tract Cancer (BTC), including early identification techniques such as molecular testing, and the current limitations in treatment strategies. It delves into ongoing developments in clinical research aimed at overcoming these limitations, with a specific focus on the MDM2/p53 pathway’s role in BTC. It encompasses subtypes and prevalence, incidence rates, prognostic factors, and both first-line and emerging treatment options.